WHAT ARE
RARE CANCERS?
Rare cancers affect fewer than 6 per 100,000 per year but collectively account for ~20-22% of all cancer diagnoses. The challenge is structural: limited expertise, thin literature, few trials — addressable with genomic profiling and specialist access
What This Means for Patients
Rare cancers affect fewer than 6 per 100,000/year (RARECARE threshold). Collectively ~20-22% of all diagnoses globally. Categories: sarcomas, NETs, mesothelioma, biliary tract, adrenocortical, rare brain tumours. Genomic profiling reveals actionable alterations (NTRK fusions, MSI-H, TMB-high) target
Key Insights
Understanding this topic is critical for rare cancer treatment planning and access decisions.
Clinical Relevance
Directly impacts treatment selection, molecular profiling decisions, and access to targeted therapies and clinical trials for rare cancer patients.
For Patients
Knowledge enables better-informed questions for oncologists, more productive specialist consultations, and active participation in treatment decisions alongside the clinical team.
Benefits and Limitations
Benefits
- Tumour-agnostic approvals transformed rare cancer treatment access
- Comprehensive genomic profiling identifies actionable alterations across tumour types
- Chinese academic centres provide cost-accessible specialist rare cancer expertise
Limitations
- Not all rare cancers carry targetable molecular alterations
- Some rare cancers genuinely have no effective treatment currently
- Specialist expertise concentrated at a small number of centres globally
Frequently Asked Questions
About This Topic
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Navigating Rare Cancer Treatment?
CancerFax connects rare cancer patients with specialist centres, molecular profiling, targeted therapy access, and clinical trial opportunities at Chinese academic centres.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.